Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:08 PM
Ignite Modification Date:
2025-12-24 @ 11:08 PM
NCT ID:
NCT06210269
Eligibility Criteria:
Inclusion Criteria:
1. Signed informed consent
2. Age 18-60 years
3. CT scan confirmed diagnosis of uncomplicated acute appendicitis.
Exclusion Criteria:
1. Complicated acute appendicitis on CT (presence of appendicolith, perforation, abscess, suspicion of tumor, or appendiceal diameter ≥ 15 mm),
2. body temperature \> 38°C,
3. age younger than 18 or older than 60 years,
4. contraindications for CT (pregnancy, lactation, allergy to contrast media or iodine, renal insufficiency with serum creatinine exceeding upper reference limit, type 2 diabetes and metformin medication),
5. severe systemic illness (malignancy, or requiring immunosuppressant medication), and
6. all contraindications and other relevant precautions to moxifloxacin (please see list below)
7. inability to co-operate and give informed consent.
Contraindications and other relevant precautions to moxifloxacin in addition to already mentioned trial exclusion criteria: Hypersensitivity to moxifloxacin, or to other quinolones Patients with a history of tendon disease/disorder related to quinolone treatment, Congenital or documented acquired QT prolongation or baseline QTc ≥500 ms, Electrolyte disturbances, particularly in uncorrected hypokalaemia, Clinically relevant bradycardia, Clinically relevant heart failure with reduced left-ventricular ejection fraction, Previous history of symptomatic arrhythmias, Concurrent use of other drugs that prolong the QT interval,
* Anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)
* Anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)
* Antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)
* Tricyclic antidepressive agents
* Certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine)
* Certain antihistaminics (terfenadine, astemizole, mizolastine)
* Others (cisapride, vincamine IV, bepridil, diphemanil).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
60 Years
Study:
NCT06210269
Study Brief:
Protocol Section:
NCT06210269